Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioVeris has entered into a new technology license agreement with Baxter Healthcare, for the rights to new components that will be used in vaccines for meningitis, sepsis and pneumonia.
Subscribe to our email newsletter
The agreement includes the rights to use Neisseria meningitidis group Y and Haemophilus influenzae type b (Hib) components for the new vaccines
These new vaccine candidates are expected to have the advantage of reducing the number of injections that a child would receive at one time.
Under the agreement, BioVeris receives exclusive rights to patents and know-how related to the manufacture, production, use, marketing, distribution and sale of the vaccine or vaccine combination candidates.
BioVeris has also paid a license issue fee and may also make additional future payments for patent costs, milestone fees for initiating and completing human clinical trials and receiving regulatory approvals. The company is also required to pay royalties on product sales.
BioVeris has already licensed patent rights for other components to be used in vaccines for the prevention of infectious disease. These new candidates are expected to complement and expand the existing intellectual property and vaccine candidates at BioVeris.